April 20 (Reuters) – AstraZeneca said on Monday its experimental treatment tozorakimab met the main goal in a late-stage trial, reflecting a sharp reduction in moderate-to-severe flare-ups of chronic obstructive pulmonary disease (COPD).
(Reporting by Prerna Bedi in Bengaluru; Editing by Sherry Jacob-Phillips)
Comments